BNTC
Benitec Biopharma Ltd
11.00$
+0.9%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -23.1% | +14.6% | -5.7% | +28.3% | -57.3% | +82.0% | -72.1% | -25.3% | +1,069.6% | +90.8% | +83.4% | |
| – | -23.7% | +14.9% | -5.6% | +27.7% | -59.7% | +90.7% | -76.6% | -22.6% | +1,285.7% | +90.7% | +84.4% | |
| – | -17.4% | -4.2% | -7.3% | +39.0% | -56.4% | +101.7% | -79.5% | -39.0% | +1,953.5% | +92.2% | +84.1% | |
| – | -17.3% | -4.3% | -7.1% | +38.8% | -56.4% | +101.7% | -79.5% | -39.0% | +1,953.5% | +92.2% | +84.1% | |
| – | +422.8% | +114.5% | +22.1% | +22.9% | -98.9% | -57.6% | -88.0% | +1,733.3% | +316.4% | -85.6% | – | |
| – | -94.8% | -158.5% | – | – | +94,799,900.0% | – | – | +722,122.2% | +384.6% | – | – | |
| – | +44.0% | -12.1% | -28.3% | +47.3% | +63.6% | -25.0% | +72.1% | -38.3% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -16.5% | -15.2% | +192.6% | +1.1% | -42.9% | -9.1% | +125.8% | +37.9% | +16.4% | -53.7% | +144.2% | |
| – | -18.0% | -16.3% | +196.1% | +3.0% | -56.9% | +20.5% | +85.0% | +57.1% | +23.8% | -63.4% | +196.6% | |
| – | – | – | – | – | – | +10.9% | +18.3% | +9.1% | +3.3% | +24.6% | +40.1% | |
| – | -31.1% | -66.7% | +218.6% | +246.0% | -80.9% | -2.8% | +54.0% | +170.1% | +18.5% | -85.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -23.2% | +53.4% | -36.2% | +20.3% | -38.2% | +95.4% | -85.6% | -93.0% | +23,290.1% | +105.9% | +81.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +23.2% | +23.3% | +20.0% | +22.1% | +19.2% | +320.6% | +90.2% | -27.9% | +641.5% | +252.4% | +28.6% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.